Evidence map›Paper›PMID 41537165›Full record

ArticleMolecular therapy. Oncology2026

Non-viral TcBuster transposon engineering of CD70-CAR natural killer cells for the treatment of osteosarcoma.

Gabrielle M Robbins, Jae-Woong Chang, Joshua B Krueger, Young Y Vue, Alexandria K Gilkey, Timothy D Folsom, Tyler Jubenville, Joseph G Skeate, Benjamin W Langworthy, Katelyn M Fitzgerald and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Gabrielle M RobbinsDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Jae-Woong ChangDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joshua B KruegerDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Young Y VueDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Alexandria K GilkeyDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Timothy D FolsomDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Tyler JubenvilleDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joseph G SkeateDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Benjamin W LangworthySchool of Public Health, University of Minnesota, Minneapolis, MN, USA.
Katelyn M FitzgeraldDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Joseph J PetersonDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Erin M StelljesDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
David A LargaespadaDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Eric P RahrmannCancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.
Beau R WebberDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Branden S MoriarityDepartment of Pediatrics, University of Minnesota, Minneapolis, MN, USA.

Funding

Deconvoluting the Ewing sarcoma genetic program using ancestry-informed human iPSC modelingR37CA276345 · NCI · UNIVERSITY OF MINNESOTA · PI Beau Richard Webber · 2023 to 2026
$2.2M
Human iPSC-Derived Chimeric Antigen Receptor Macrophages to Modulate Inflammation and Combat Tau-Induced PathologyR61AG090358 · NIA · UNIVERSITY OF MINNESOTA · PI Jonathan N Sachs, Beau Richard Webber · 2025 to 2026
$1.5M
Multiplex Engineered Human Lymphocytes for Therapeutic Protein DeliveryR21AI163731 · NIAID · UNIVERSITY OF MINNESOTA · PI WEBBER, BEAU RICHARD · 2021 to 2022
$426k
NCI NIH HHS R37 CA276345NIAID NIH HHS R21 AI163731NIA NIH HHS R61 AG090358
6 · The paper itself

Abstract

Osteosarcoma (OSA) is the most common primary bone tumor in children and adolescents, yet outcomes have remained largely unchanged for over 40 years. While chimeric antigen receptor (CAR) T cell therapy has shown success in blood cancers, it faces major limitations in solid tumors due to immune evasion, antigen loss, and immunosuppressive tumor microenvironments. Natural killer (NK) cells offer several advantages over T cells, including multiple killing mechanisms and lower risks of graft-versus-host disease, neurotoxicity, and cytokine release syndrome, making them promising candidates for off-the-shelf cell therapies. However, unmodified NK cells have shown limited efficacy in clinical settings due to poor engraftment, persistence, and tumor-mediated suppression. To overcome these barriers, we developed a cost-effective method to engineer CAR NK cells targeting CD70, a tumor antigen overexpressed in relapsed and metastatic OSA. We further enhanced these cells by incorporating soluble interleukin-15 (IL-15) and a dominant-negative TGF-β receptor, creating "armored" CAR NK cells. These engineered cells resist transforming growth factor β (TGF-β) suppression, secrete IL-15, and demonstrate improved cytotoxicity, persistence, and tumor homing in both

Indexed as

adoptive cell therapyCAR NK cellsCD70chimeric antigen receptorimmunotherapymetastatic osteosarcomaMT: Regular IssueNK cell persistenceosteosarcomapediatric bone tumorrelapsed osteosarcomasolid tumorsTMEtumor immune evasiontumor microenvironment

Identifiers

PMID41537165
PMCPMC12796739

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.